4-dimethylamino-6-methylpyrimidine | 23448-83-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-dimethylamino-6-methylpyrimidine
• 英文别名: 4-Dimethylamino-2-methylmercapto-6-methyl-pyrimidin；4-Dimethylamino-6-methyl-2-methylthiopyrimidin；4-dimethylamino-6-methyl-2-methylsulfanylpyrimidine；4-dimethylamino-6-methyl-2-(methylthio)pyrimidine；dimethyl-(6-methyl-2-methylsulfanyl-pyrimidin-4-yl)-amine；N,N,6-trimethyl-2-(methylsulfanyl)pyrimidin-4-amine；N,N,6-trimethyl-2-methylsulfanylpyrimidin-4-amine
• CAS: 23448-83-1
• 化学式: C₈H₁₃N₃S
• 分子量: 183.277
• InChiKey: KCKYIYULUDUYMR-UHFFFAOYSA-N

物化性质

• 熔点：
  43-44 °C
• 沸点：
  162-165 °C(Press: 12 Torr)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  silver picrate 、 4-dimethylamino-6-methylpyrimidine 以 甲醇 为溶剂， 反应 2.0h， 以81%的产率得到
  参考文献：
  名称：

  Metal binding properties of pyrimidinophanes and their acyclic counterparts

  摘要：

  一系列含有尿嘧啶和2-硫胞嘧啶单元并通过聚亚甲基间隔相连的非环和宏环核碱衍生物被制备出来。间隔的长度以及进入化合物结构的硫原子的氧化数被改变。通过X射线分析确定了含有六亚甲基和七亚甲基连接体的嘧啶冠醚的晶体结构。通过液体萃取和1H NMR滴定实验研究了嘧啶冠醚及其非环对应物的金属离子结合性质。含有2-硫胞嘧啶片段的化合物显示出对Ag+离子的高选择性萃取。确定银络合物的化学计量比和结合常数。这些络合物的抗菌活性也进行了讨论。

  DOI：

  10.1039/c3ra47571a
• 作为产物：
  描述：

  6-Methyl-2-methylthio-4-tosyloxypyrimidin 、 二甲胺 生成 4-dimethylamino-6-methylpyrimidine
  参考文献：
  名称：

  JAMES S. R., J. CHEM. RES. SYNOP., 1979, NO 4, 125, (M 1579-1592)

  摘要：

  DOI：

文献信息

• 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety
  申请人：——

  公开号：US20040082587A1

  公开（公告）日：2004-04-29

  This invention is directed to pyrimidine derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

  这项发明涉及选择性拮抗剂对GalR3受体的嘧啶衍生物。该发明提供了一种包含本发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了一种通过结合本发明化合物的治疗有效量和药用载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投与一定量的本发明化合物以治疗受试者的抑郁症和/或焦虑症。该发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者投与一种含有药用载体和GalR3受体拮抗剂的组合物的治疗有效量。
• Silver mediated duplex-type complexes of pyrimidinophanes and their acyclic counterparts
  作者：Sergey N. Podyachev、Alexey N. Masliy、Vyacheslav E. Semenov、Victor V. Syakaev、Svetlana N. Sudakova、Julia K. Voronina、Vladimir T. Ivanov、Andrey M. Kuznetsov、Edward L. Gogolashvili、Vladimir S. Reznik、Alexander I. Konovalov

  DOI：10.1039/c4ra14070b

  日期：——

  Pyrimidinophanes revealed high extraction selectivity for Ag⁺ ions and afforded Ag⁺ mediated duplex-type complexes. Such coordination is realized due to the N1-atoms of the 2-thiocytosine fragments and the polymethylene spacer linking amine groups.

  嘌呤环戊烷衍生物显示出对Ag+离子的高萃取选择性，并形成了Ag+介导的双链型配合物。这种配位是由于2-硫基胞嘧啶片段的N1原子和连接氨基的聚亚甲基间隔所实现的。
• Study of the protonation (methylation) position and tautomeric structure of thiopyrimidine derivatives by 2D 1H—15H NMR HSQC/HMBC. Experimental approach and theoretical modeling
  作者：A. V. Kozlov、V. E. Semenov、A. S. Mikhailov、A. V. Il’yasov、V. S. Reznik、Sh. K. Latypov

  DOI：10.1007/s11172-009-0008-4

  日期：2009.1

  Two-dimensional 1H—15N NMR HSQC/HMBC experiments enable the unambiguous determination of the protonation (methylation) position and tautomeric structure of nitrogen-containing heterocycles. In investigated thiopyrimidines protonation (or methylation) occurs at the N(1) atom of the pyrimidine ring. The tautomeric structures of these compounds were established based on the analysis of 1H—15N NMR spectra. Ab initio calculations of chemical shifts (GIAO B3LYP/6-31G(d)//HF/6-31G) are in full agreement with experimental values. The stability of various protonated (methylated) and tautomeric species is explained in terms of a thermodynamic approach.

  二维 1H-15N NMR HSQC/HMBC 实验能够明确确定含氮杂环的质子化（甲基化）位置和同分异构体结构。在所研究的噻吩嘧啶中，质子化（或甲基化）发生在嘧啶环的 N（1）原子上。根据 1H-15N NMR 光谱分析，确定了这些化合物的同分异构体结构。化学位移的 Ab initio 计算（GIAO B3LYP/6-31G(d)//HF/6-31G）与实验值完全一致。热力学方法解释了各种质子化（甲基化）和同分异构体的稳定性。
• Pyrimidinophane p-toluenesulfonate—Water-soluble pyrimidine-containing macrocycles
  作者：V. E. Semenov、A. S. Mikhailov、E. S. Romanova、A. D. Voloshina、N. V. Kulik、S. Yu. Uraleva、A. V. Kozlov、Sh. K. Latypov、V. S. Reznik

  DOI：10.1134/s1070363209010216

  日期：2009.1

  Reactions of pyrimidinophanes containing two 6-methylthiocytosine and one 6-methyluracil fragments with methyl p-toluenesulfonate gave amphiphilic macrocyclic bis-p-toluenesulfonates. Despite the presence of several reaction centers in the initial pyrimidinophane molecules, methylation occurred only at the N-1 atom (with quaternization) of the 6-methylthiocytosine fragments. Bacteriostatic and fungistatic activity of the products was estimated.